MedTrace Logo

Dexmedetomidine Neuroprotection in Pediatric Cardiac Surgery

NCT04484922 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2022-02-02

No results posted yet for this study

Summary

Neurodevelopmental disability is the most significant complication for survivors of infant surgery for congenital heart disease. In this study we sought to determine if intraoperative continuous infusion of dexmedetomidine are associated with neurodevelopmental outcomes at 12 months.

Conditions

  • Congenital Heart Disease

Interventions

DRUG

Dexmedetomidine

continuous infusion of dexmedetomidine during the surgery

DRUG

Normal saline

continuous infusion of normal saline during the surgery

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-25
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04484922 on ClinicalTrials.gov